AWH - Rasio utang marang kapitalisasi buku Aspira Women's Health Inc

Logo grafis Aspira Women's Health (AWH)

Aspira Women's Health is advancing oncology diagnostics, strengthening its position through FDA certifications. The percentage of debt participation in balance sheet capital demonstrates reliability dynamics, where the value of 0.00 characterizes this level. The financial base relies on alliances with clinics, and localization in the US minimizes geopolitical risks, limiting them only to a possible shortage of Asian consumables.

Aspira Women's Health - Utang-utang marang kapitalisasi buku AWH (periode 04.07.2022 - 26.04.2025)
Barang unggulan Vermillion

This ratio determines the proportion of borrowed liabilities relative to the company's total equity. It measures the degree of financial leverage and the company's dependence on external borrowing. For Aspira Women's Health (AWH), this balance is critical when scaling the OVA1 diagnostic platform. Stable demand for molecular tests allows the company to control its debt load. By analyzing the dynamics of the debt-to-equity ratio, an investor can assess the risks of asset impairment.

Karo sapa Aspira Women's Health saingan

Utang-utang marang kapitalisasi buku A (Agilent Technologies)|questdiagnostics.com - Utang-utang marang kapitalisasi buku|Illumina (ILMN) - Rasio utang marang kapitalisasi buku|EXAS - Rasio utang marang nilai buku|RVTY: Utang-utang marang kapitalisasi buku|BIO (Bio-Rad Corp) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Anbio Biotechnology|Rasio utang marang kapitalisasi buku soterahealth.com (SHC)|QuidelOrtho Corporation - Utang marang nilai buku|Utang-utang marang nilai buku OPK (OPKO Health Inc)|Rasio utang marang kapitalisasi buku CDNA|Utang-utang marang aset resik Maravai MRVI|Utang-utang marang kapitalisasi buku FLGT (Fulgent Genetics, Inc.)|LAB: Utang-utang marang aset resik|Cytek Biosciences - Rasio utang marang kapitalisasi buku|OraSure Technologies, Inc. (OSUR) - Utang-utang marang aset resik|XGN (Exagen Inc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku MDXH|LUCD (Lucid Diagnostics Inc.) - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik PRE (prenetics.com)|Insight Molecular Diagnostics Inc (IMDX) - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku Trinity Biotech PLC TRIB|Utang-utang marang kapitalisasi buku PRPH (ProPhase)|AIMD: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku Co-Diagnostics, Inc. CODX|heartsciences.com (HSCS) - Rasio utang marang aset resik|BMRA (Biomerica) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Cardio Diagnostics Holdings, Inc. (CDIO)|Virax Biolabs Group Ltd (VRAX) - Utang marang nilai buku|Rasio utang marang aset resik Bluejay Diagnostics Corp BJDX|Accelerate Diagnostics - Utang marang nilai buku|centogene.com - Utang marang nilai buku|ENZ (Enzo) - Rasio utang marang kapitalisasi buku|FRES: Utang-utang marang nilai buku|GENE (gtglabs.com) - Rasio utang marang kapitalisasi buku|23andMe Inc (ME) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku PMD (Psychemedics)